RTI Biologics Launches New Line Of Biologic Implants At Americas Hernia Society’s 15th Annual Hernia Repair Conference, March 13-16

RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, is launching a new line of biologic implants used in hernia repair procedures at the Americas Hernia Society’s 15 th Annual Hernia Repair Conference held at JW Marriott Grande Lakes, Orlando, Fla., March 13-16. The implants will be distributed directly by the company’s new Surgical Specialties business unit.

Tutopatch™ bovine pericardium and Tutomesh™ fenestrated bovine pericardium are non-crosslinked acellular collagen matrices that offer a safe and natural biologic option for hernia repair. The implants offer equivalent strength 1 to the leading implant in the market and are sterilized through RTI’s Tutoplast ® Tissue Sterilization Process. The Tutopatch and Tutomesh implants are clinically proven and have been implanted by surgeons in Europe for more than 10 years.

Cortiva™ allograft dermis offers high mechanical strength 2,3, rapid cellular repopulation 4,5,6 and features a faster rehydration time compared with other dermis grafts (rehydrating in 30 seconds on average) 7. Dermis is collagenous connective tissue with three-dimensional intertwined fibers. The Cortiva implant is also sterilized through RTI’s Tutoplast Tissue Sterilization Process rendering non-crosslinked acellular dermal matrix that retain mechanical properties of native dermis.

“We are excited to begin direct distribution of Tutopatch and Tutomesh bovine pericardium and Cortiva allograft dermis through our newly developed distribution force for Surgical Specialties,” said Brian K. Hutchison, RTI president and CEO. “Surgeons in need of biologics for hernia repair can expect safe, quality implants from a provider they trust. We will be filling out our hernia portfolio in the coming months with the introduction of our porcine dermis implant.”

The Tutoplast Tissue Sterilization Process is a validated chemical sterilization process that thoroughly penetrates tissue, removing antigenicity and inactivating pathogens. Terminal sterilization using low dose gamma irradiation achieves a sterility assurance level (SAL) of 10 -6.

AHS Luncheon Symposium

In addition to launching the implant line at the AHS conference, RTI will also host a luncheon presentation and discussion on Wednesday, March 13 from 12 to 1 p.m. featuring David Nocca, M.D., Ph.D. from the Department of Digestive Surgery at the University Hospital of Montpellier in Montpellier, France. Nocca will present “Biosurgical Technology and Technique-Based Considerations for Ventral Hernia Repair.”

If you liked this article you might like

Integra's Massive Run-Up Expected to Continue as J&J's Surgical Business Joins the Fold

Strong And Under The Radar: RTI Surgical (RTIX)

4 Health Care Stocks Under $10 to Watch

4 Stocks Under $10 in Breakout Territory

RTI Biologics Inc. Stock Downgraded (RTIX)